These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [MPTP and Parkinson's disease]. Imai H. No To Shinkei; 1988 Nov; 40(11):1011-24. PubMed ID: 3064783 [No Abstract] [Full Text] [Related]
5. Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals. Kopin IJ. Adv Neurol; 1987 Nov; 45():137-44. PubMed ID: 3493621 [No Abstract] [Full Text] [Related]
6. Street-drug contaminant causing parkinsonism. Centers for Disease Control (CDC). MMWR Morb Mortal Wkly Rep; 1984 Jun 22; 33(24):351-2. PubMed ID: 6427583 [No Abstract] [Full Text] [Related]
7. MPTP in animal models of Parkinson's disease. Kopin IJ, Schoenberg DG. Mt Sinai J Med; 1988 Jan 22; 55(1):43-9. PubMed ID: 3126391 [No Abstract] [Full Text] [Related]
8. [Experimental model of Parkinson disease induced by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)]. Renkawek K. Neuropatol Pol; 1986 Jan 22; 24(1):1-8. PubMed ID: 3489205 [No Abstract] [Full Text] [Related]
9. [MPTP: a new chapter in the history of Parkinson's disease]. Piccinin GL, Piccirilli M, Finali G, Stefano E. Riv Neurol; 1989 Jan 22; 59(3):103-7. PubMed ID: 2688042 [Abstract] [Full Text] [Related]
10. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction]. Nishi K, Kondo T, Narabayashi H. No To Shinkei; 1987 Jul 22; 39(7):663-72. PubMed ID: 3314916 [Abstract] [Full Text] [Related]
12. MPTP and parkinsonism. Bianchine JR, McGhee B. Ration Drug Ther; 1985 Feb 22; 19(2):5-7. PubMed ID: 3876575 [No Abstract] [Full Text] [Related]
13. Early parkinsonism. Calne DB, Stoessl AJ. Clin Neuropharmacol; 1986 Feb 22; 9 Suppl 2():S3-8. PubMed ID: 3297316 [Abstract] [Full Text] [Related]
14. MPTP: a pharmacological tool to study parkinsonism. Kulkarni SK, Mehta AK, Aley KO, Shukla VK. Methods Find Exp Clin Pharmacol; 1986 Aug 22; 8(8):485-9. PubMed ID: 3489146 [Abstract] [Full Text] [Related]
15. Parkinson's disease: current view. Langston JW. Am Fam Physician; 1987 Mar 22; 35(3):201-6. PubMed ID: 3103408 [Abstract] [Full Text] [Related]
16. MPTP and the aetiology of Parkinson's disease. Clinical implications. London, June 27, 1985. J Neural Transm Suppl; 1986 Mar 22; 20():1-81. PubMed ID: 3489069 [No Abstract] [Full Text] [Related]
17. The MPTP model of Parkinson's disease. Smeyne RJ, Jackson-Lewis V. Brain Res Mol Brain Res; 2005 Mar 24; 134(1):57-66. PubMed ID: 15790530 [Abstract] [Full Text] [Related]
18. Parkinson's disease in 1984: an update. Lang AE, Blair RD. Can Med Assoc J; 1984 Nov 01; 131(9):1031-7. PubMed ID: 6388779 [Abstract] [Full Text] [Related]
19. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. Chiueh CC, Markey SP, Burns RS, Johannessen JN, Jacobowitz DM, Kopin IJ. Psychopharmacol Bull; 1984 Nov 01; 20(3):548-53. PubMed ID: 6332333 [No Abstract] [Full Text] [Related]
20. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Langston JW, Ballard PA. N Engl J Med; 1983 Aug 04; 309(5):310. PubMed ID: 6602944 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]